Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per letter attached27-10-2021
27-10-2021
Tech Query: What is the long-term outlook for Sun Pharma and Wockhardt?
I have shares of Sun Pharmaceuticals and Wockhardt. Please give the long-term outlook for these two stocks.Pradeep KabraSun Pharmaceutical Industries23-10-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201520-10-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma to announce second-quarter results on November 02, 202119-10-2021
Sun Pharmaceutical Industries Ltd - 524715 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ashok BhutaDesignation :- Any Other19-10-2021
Sun Pharmaceutical Industries Ltd - 524715 - Shareholding for the Period Ended September 30, 2021
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here18-10-2021
Sun Pharmaceutical Industries Ltd - 524715 - Certificate from CEO/CFO
Please find enclosed certificate as per para 4 of Annexure II to the SEBI Circular No. SEBI/HO/DDHS/DDHS/CIR/P/2019/115 dated October 22, 2019.14-10-2021
Broker's call: Sun Pharma (Buy)
Motilal OswalSun Pharma (Buy)Target: 960CMP: 842.5After having toughed out for more than three years in the US, its flagship product Ilumya is conti13-10-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Notice Of The Board Meeting For Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2021.
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2021 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, November 02, 2021 to inter alia consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021. Further, kindly note that pursuant to the Company''s Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons, commenced on October 01, 2021, and shall end on November 04, 2021 i.e. after 48 hours of the declaration of financial results of the Company on November 02, 2021. This is for your information and dissemination.12-10-2021
Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed certificate dated October 8, 2021 for the quarter ended September 30, 2021 received from M/s. Link Intime (India) Private Limited, Registrar & Share Transfer Agent of the Company. This is for your information and record.12-10-2021